President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers …
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name …
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing. Extreme-photographer | E+ | Getty Images A multitude of factors are coming together to bring a …
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional …
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of …
The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell …
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a …
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. …
U.S. President Donald Trump shakes hands with President of the European Commission Ursula von der Leyen as he announces a trade deal with the EU at Trump Turnberry golf club on July 27, 2025 in Turnberry, Scotland. U.S. Andrew Harnik | Getty Images News | Getty Images The U.S. and …
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here …